Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 9/20 | 0.38 |
| ▸ | EGFR | P00533 | 6/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | GBA1 | P04062 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | NSD2 | O96028 | 1/20 | 0.33 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21474535 | 0.88 | ERBB2 (0.40) | ERBB2EGFRCHEK1ALDH1A1NSD2 | |
| SCHEMBL22232285 | 0.81 | EGFR (0.35) | ERBB2EGFRCHEK1ALDH1A1NSD2 | |
| SCHEMBL21473392 | 0.81 | EGFR (0.35) | ERBB2EGFRCHEK1ALDH1A1NSD2 | |
| SCHEMBL22232287 | 0.81 | EGFR (0.35) | ERBB2EGFRCHEK1ALDH1A1NSD2 | |
| SCHEMBL27194812 | 0.80 | TBK1 (0.38) | ERBB2EGFRCHEK1ALDH1A1KDM4E | |
| SCHEMBL21481184 | 0.80 | TBK1 (0.38) | ERBB2EGFRCHEK1ALDH1A1KDM4E | |
| SCHEMBL25987141 | 0.79 | ERBB2 (0.37) | ERBB2EGFRCHEK1ALDH1A1KDM4E | |
| SCHEMBL30988715 | 0.76 | ERBB2 (0.43) | ERBB2EGFRCHEK1NSD2 | |
| SCHEMBL30988726 | 0.74 | ERBB2 (0.53) | ERBB2EGFR | |
| SCHEMBL30988768 | 0.74 | ERBB2 (0.34) | ERBB2CHEK1TBK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11713306-B2 | 5-substituted difluoropiperidine compounds with blood-brain barrier penetrable capability | WAYSHINE BIOPHARM HOLDING LIMITED (KY) | 2023-08-01 | — | — | US | disclosed |
| US-11713306-B2 | 5-substituted difluoropiperidine compounds with blood-brain barrier penetrable capability | WAYSHINE BIOPHARM HOLDING LIMITED (KY) | 2023-08-01 | — | — | US | disclosed |
| EP-3778589-B1 | 5-SUBSTITUTED DIFLUOROPIPERIDINE COMPOUND CAPABLE OF PASSING THROUGH BLOOD-BRAIN BARRIER | WEISHANG SHANGHAI BIO PHARMACEUTICAL CO LTD (CN) | 2022-05-11 | — | — | EP | disclosed |
| US-20210017159-A1 | 5-SUBSTITUTED DIFLUOROPIPERIDINE COMPOUNDS WITH BLOOD-BRAIN BARRIER PENETRABLE CAPABILITY | WEISHANG (SHANGHAI) BIO-PHARMACEUTICAL CO., LTD. (CN) | 2021-01-21 | — | — | US | disclosed |
| WO-2019196622-A1 | 5-SUBSTITUTED DIFLUOROPIPERIDINE COMPOUND CAPABLE OF PASSING THROUGH BLOOD-BRAIN BARRIER | 威尚（上海）生物医药有限公司 | 2019-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11713306-B2 | 5-substituted difluoropiperidine compounds with blood-brain barrier penetrable capability | FYN, KDR, FLT1 | ERBB2 7/4885EGFR 11/4885CHEK1 3140/4885 |
| US-20210017159-A1 | 5-SUBSTITUTED DIFLUOROPIPERIDINE COMPOUNDS WITH BLOOD-BRAIN BARRIER PENETRABLE CAPABILITY | FYN, KDR, FLT1 | ERBB2 7/4885EGFR 11/4885CHEK1 3140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.